HER2 positive non-squamous non-small cell lung cancer w/ tyrosine kinase domain activating mutations

HER2-positive non-squamous non-small cell lung cancer with tyrosine kinase domain activating mutations is a distinct molecular subtype of epithelial lung malignancy, most frequently manifesting as adenocarcinoma within the respiratory system Clinically, these tumors behave aggressively, frequently presenting at advanced or metastatic stages, and serve as actionable genomic targets identified by molecular profiling

This condition primarily affects adults, often occurring with higher frequency among female non-smokers Clinically, these tumors behave aggressively, frequently presenting at advanced or metastatic stages, and serve as actionable genomic targets identified by molecular profiling

This condition primarily affects adults, often occurring with higher frequency among female non-smokers

Pathophysiologically, it is defined by somatic activating alterations—most commonly in-frame insertions within exon 20 of the HER2 (*ERBB2*) tyrosine kinase domain—that induce constitutive receptor phosphorylation and downstream MAPK and PI3K/Akt pathway activation, driving malignant cell proliferation and survival

Pathophysiologically, it is defined by somatic activating alterations—most commonly in-frame insertions within exon 20 of the HER2 (*ERBB2*) tyrosine kinase domain—that induce constitutive receptor phosphorylation and downstream MAPK and PI3K/Akt pathway activation, driving malignant cell proliferation and survival

Clinically, these tumors behave aggressively, frequently presenting at advanced or metastatic stages, and serve as actionable genomic targets identified by molecular profiling